Spun out of the University of North Carolina at Chapel Hill, Altis Biosystems, Inc. is anchored in a patented stem cell platform designed for drug screening and microbiome research purposes, to recreate the human intestinal epithelium in a high-throughput format. Describing thmselves as a next generation stem cell technologies to test the effects of medicines, diseases, and more on human biology. the firm offers various services to include toxicology, permeability, ELISA, transport, custom cell isolation, and others. The primary objective of Altis is to make drug discovery faster, cheaper, safer, and - specifically - to reduce the need for animal testing. Working on Next Generation in-vitro drug screening platforms, the firm has developed a stem cell technology that recreates the human intestinal epithelium in a 2D or 3D layer of intestinal stem and differentiated cells and which can be used for compound screening, microbiome research and disease modeling.
